Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16399124 | 0.84 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2USP2 | |
| SCHEMBL16399123 | 0.84 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2USP2 | |
| SCHEMBL30468463 | 0.80 | SMYD2 (0.41) | SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL28743420 | 0.78 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL18187896 | 0.75 | USP2 (0.36) | USP2ALDH1A1ALOX15TDP1 | |
| SCHEMBL28917486 | 0.75 | SMYD2 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2TDP1 | |
| SCHEMBL30955729 | 0.75 | SMYD2 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL30955759 | 0.75 | SMYD2 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL30726327 | 0.75 | SMYD2 (0.43) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL5566651 | 0.74 | SMYD2 (0.50) | SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116234800-A | Copper complexes for the treatment of neurodegenerative disorders | ALS治疗发展学会 | 2023-06-06 | — | — | CN | disclosed |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE, | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | SMYD2 3596/4885CYP3A4 4471/4885HTT 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.